- Home
- COEP vs WHWK Comparison
COEP vs WHWK Comparison
Compare COEP & WHWK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- COEP
- WHWK
- Stock Information
- Founded
- COEP 2017
- WHWK 2007
- Country
- COEP United States
- WHWK United States
- Employees
- COEP N/A
- WHWK N/A
- Industry
- COEP Biotechnology: Biological Products (No Diagnostic Substances)
- WHWK Biotechnology: Pharmaceutical Preparations
- Sector
- COEP Health Care
- WHWK Health Care
- Exchange
- COEP Nasdaq
- WHWK Nasdaq
- Market Cap
- COEP 86.0M
- WHWK 95.2M
- IPO Year
- COEP N/A
- WHWK N/A
- Fundamental
- Price
- COEP $15.29
- WHWK $2.11
- Analyst Decision
- COEP
- WHWK
- Analyst Count
- COEP 0
- WHWK 0
- Target Price
- COEP N/A
- WHWK N/A
- AVG Volume (30 Days)
- COEP 66.5K
- WHWK 109.9K
- Earning Date
- COEP 11-12-2025
- WHWK 11-15-2025
- Dividend Yield
- COEP N/A
- WHWK N/A
- EPS Growth
- COEP N/A
- WHWK N/A
- EPS
- COEP N/A
- WHWK N/A
- Revenue
- COEP $263,555.00
- WHWK $21,596,000.00
- Revenue This Year
- COEP N/A
- WHWK N/A
- Revenue Next Year
- COEP N/A
- WHWK N/A
- P/E Ratio
- COEP N/A
- WHWK N/A
- Revenue Growth
- COEP N/A
- WHWK N/A
- 52 Week Low
- COEP $2.31
- WHWK $1.39
- 52 Week High
- COEP $19.19
- WHWK $3.81
- Technical
- Relative Strength Index (RSI)
- COEP 49.85
- WHWK 58.00
- Support Level
- COEP $14.90
- WHWK $1.87
- Resistance Level
- COEP $16.17
- WHWK $2.12
- Average True Range (ATR)
- COEP 1.17
- WHWK 0.13
- MACD
- COEP -0.30
- WHWK -0.00
- Stochastic Oscillator
- COEP 11.94
- WHWK 52.27
About COEP Coeptis Therapeutics Holdings Inc.
Coeptis Therapeutics Holdings Inc is a biopharmaceutical company developing cell therapy platforms for patients with cancer. The company's product portfolio consists of multi-antigen CAR T technology licensed from the University of Pittsburgh (SNAP-CAR), a cell therapy technology (CD38-GEAR-NK), and an in vitro diagnostic (CD38-Diagnostic) targeting CD38-related cancers, which the company is developing with VyGen-Bio and medical researchers at the Karolinska Institutet.
About WHWK Whitehawk Therapeutics Inc. Common Stock
Whitehawk Therapeutics Inc is a preclinical stage oncology therapeutics. The company is engaged in applying technologies to established tumor biology to efficiently deliver improved cancer treatments. The company's three-asset ADC portfolio is engineered to overcome the limitations of first-generation predecessors to deliver a meaningful impact for patients with difficult-to-treat cancers.